methylene blue has been researched along with Nervous System Disorders in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Alexandrova, OP; Fedorov, AV; Genrikhs, EE; Isaev, NK; Novikova, SV; Stelmashook, EV; Voronkov, DN | 1 |
| Calabrese, EJ; Kozumbo, WJ | 1 |
| Albuquerque, AAS; Arcencio, L; Baldo, CF; Basile-Filho, A; Celotto, AC; Evora, PRB; Silva, LM | 1 |
| Namba, E; Sugie, H | 1 |
| Beri, R; Shord, SS; Sweiss, KI | 1 |
| Martindale, SJ; Stedeford, JC | 1 |
| Gillman, PK | 1 |
| Bowers, RJ; Espinosa, FJ; Gross, PM; Ho, LT; Nag, S; Pang, JJ; Weaver, DF | 1 |
| Gill, HS; Singh, N | 1 |
3 review(s) available for methylene blue and Nervous System Disorders
| Article | Year |
|---|---|
The hormetic dose-response mechanism: Nrf2 activation.
Topics: Alzheimer Disease; Animals; Drug Discovery; Hormesis; Humans; Light; Methylene Blue; Nervous System Diseases; NF-E2-Related Factor 2; Oxidative Stress; Phytochemicals; Protective Agents; Radiation, Ionizing | 2021 |
Why Methylene Blue Have to Be Always Present in the Stocking of Emergency Antidotes.
Topics: Anaphylaxis; Antidotes; Clinical Trials as Topic; Critical Care; Drug Overdose; Emergency Service, Hospital; Evidence-Based Medicine; Humans; Methylene Blue; Multiple Trauma; Nervous System Diseases; Poisoning | 2018 |
Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.
Topics: Adult; Albumins; Antineoplastic Agents, Alkylating; Bilirubin; Brain Diseases; Cohort Studies; Enzyme Inhibitors; Female; Hemoglobins; Humans; Ifosfamide; Male; Methylene Blue; Middle Aged; Nervous System Diseases; Obesity; Retrospective Studies; Risk Factors; Sarcoma; Sex Factors | 2008 |
6 other study(ies) available for methylene blue and Nervous System Disorders
| Article | Year |
|---|---|
The single intravenous administration of methylene blue after traumatic brain injury diminishes neurological deficit, blood-brain barrier disruption and decrease in the expression of S100 protein in rats.
Topics: Administration, Intravenous; Animals; Blood-Brain Barrier; Brain Injuries, Traumatic; Cells, Cultured; Enzyme Inhibitors; Gene Expression; Hand Strength; Male; Methylene Blue; Nervous System Diseases; Neuroprotective Agents; Rats; Rats, Wistar; S100 Proteins | 2020 |
[Progress in the diagnoses and treatment for hereditary neurological and muscular disorders. Introductory remarks].
Topics: Disease Susceptibility; Humans; Methylene Blue; Muscular Diseases; Nervous System Diseases; Pathology, Molecular | 2010 |
Neurological sequelae following methylene blue injection for parathyroidectomy.
Topics: Female; Humans; Indicators and Reagents; Methylene Blue; Middle Aged; Nervous System Diseases; Parathyroidectomy; Postoperative Complications | 2003 |
Methylene blue implicated in potentially fatal serotonin toxicity.
Topics: Drug Interactions; Humans; Indicators and Reagents; Methylene Blue; Nervous System Diseases; Postoperative Complications; Selective Serotonin Reuptake Inhibitors | 2006 |
Neurotoxicity in conscious rats following intraventricular SNAP, a nitric oxide donor.
Topics: Acid-Base Equilibrium; Animals; Behavior, Animal; Blood Chemical Analysis; Brain; Brain Chemistry; Guanylate Cyclase; Hemodynamics; Injections, Intraventricular; Male; Methylene Blue; Nervous System Diseases; Nitric Oxide; Nitroprusside; Penicillamine; Rats; Rats, Sprague-Dawley; S-Nitroso-N-Acetylpenicillamine | 1994 |
Relationship of neurological diseases to Toxoplasma gondii antibodies.
Topics: Adolescent; Adult; Aged; Antibodies; Humans; Methylene Blue; Middle Aged; Nervous System Diseases; Serologic Tests; Toxoplasma | 1972 |